Movement Alert｜INNOVENT BIO Rises 5.77% in Regular Trading, H1 Product Revenue Exceeds RMB 8.2 Billion with 55%+ YoY Growth

Market Focus08-05 09:34

On August 5, INNOVENT BIO rose 5.77% in regular trading, trading at HKD 91.25/share, with turnover of HKD 172 million.

On the news front, the company released an insider information announcement disclosing that its product revenue for the first half of the year exceeded RMB 8.2 billion, representing year-over-year growth of more than 55%. Notably, second-quarter product revenue alone surpassed RMB 4.3 billion, with an approximate 60% year-over-year increase, marking a significant acceleration in growth momentum.

According to the announcement, revenue growth was primarily driven by core products including Xinermei, Xinbile, and Xinbimin. The company also entered into a commercialization agreement with Eli Lilly regarding Weize in mainland China, further enriching its commercialized product portfolio. Earlier, multiple brokerages including CLSA and CMB International had issued bullish ratings on the stock, with CLSA raising its target price to HKD 139.9 and maintaining an Outperform rating, citing the company's strong R&D capabilities validated by multiple overseas licensing deals.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1127813339?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 09:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1127813339","market":"us","top_or_hot":-1,"title":"Movement Alert｜INNOVENT BIO Rises 5.77% in Regular Trading, H1 Product Revenue Exceeds RMB 8.2 Billion with 55%+ YoY Growth","media":"Market Focus","content":"<p><p>On August 5, INNOVENT BIO rose 5.77% in regular trading, trading at HKD 91.25/share, with turnover of HKD 172 million.</p><p>On the news front, the company released an insider information announcement disclosing that its product revenue for the first half of the year exceeded RMB 8.2 billion, representing year-over-year growth of more than 55%. Notably, second-quarter product revenue alone surpassed RMB 4.3 billion, with an approximate 60% year-over-year increase, marking a significant acceleration in growth momentum.</p><p>According to the announcement, revenue growth was primarily driven by core products including Xinermei, Xinbile, and Xinbimin. The company also entered into a commercialization agreement with Eli Lilly regarding Weize in mainland China, further enriching its commercialized product portfolio. Earlier, multiple brokerages including CLSA and CMB International had issued bullish ratings on the stock, with CLSA raising its target price to HKD 139.9 and maintaining an Outperform rating, citing the company's strong R&D capabilities validated by multiple overseas licensing deals.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜INNOVENT BIO Rises 5.77% in Regular Trading, H1 Product Revenue Exceeds RMB 8.2 Billion with 55%+ YoY Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜INNOVENT BIO Rises 5.77% in Regular Trading, H1 Product Revenue Exceeds RMB 8.2 Billion with 55%+ YoY Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-05 09:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 5, INNOVENT BIO rose 5.77% in regular trading, trading at HKD 91.25/share, with turnover of HKD 172 million.</p><p>On the news front, the company released an insider information announcement disclosing that its product revenue for the first half of the year exceeded RMB 8.2 billion, representing year-over-year growth of more than 55%. Notably, second-quarter product revenue alone surpassed RMB 4.3 billion, with an approximate 60% year-over-year increase, marking a significant acceleration in growth momentum.</p><p>According to the announcement, revenue growth was primarily driven by core products including Xinermei, Xinbile, and Xinbimin. The company also entered into a commercialization agreement with Eli Lilly regarding Weize in mainland China, further enriching its commercialized product portfolio. Earlier, multiple brokerages including CLSA and CMB International had issued bullish ratings on the stock, with CLSA raising its target price to HKD 139.9 and maintaining an Outperform rating, citing the company's strong R&D capabilities validated by multiple overseas licensing deals.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信达生物","start_time":0,"source_url":"","article_id":"1127813339","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127813339","pubTimestamp":1785893654,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 5, INNOVENT BIO rose 5.77% in regular trading, trading at HKD 91.25/share, with turnover of HKD 172 million.On the news front, the company released an insider information announcement...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"动向提醒|信达生物常规交易大涨5.77%，上半年产品收入超82亿元，同比增长55%以上","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"On August 5, INNOVENT BIO rose 5.77% in regular trading, trading at HKD 91.25/share, with turnover of HKD 172 million.On the news front, the company released an insider information announcement disclosing that its product revenue for the first half of the year exceeded RMB 8.2 billion, representing year-over-year growth of more than 55%. Notably, second-quarter product revenue alone surpassed RMB 4.3 billion, with an approximate 60% year-over-year increase, marking a significant acceleration in growth momentum.According to the announcement, revenue growth was primarily driven by core products including Xinermei, Xinbile, and Xinbimin. The company also entered into a commercialization agreement with Eli Lilly regarding Weize in mainland China, further enriching its commercialized product portfolio. Earlier, multiple brokerages including CLSA and CMB International had issued bullish ratings on the stock, with CLSA raising its target price to HKD 139.9 and maintaining an Outperform rating, citing the company's strong R&D capabilities validated by multiple overseas licensing deals.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1127813339","isCrawlerRequest":true}